Association of JAK2V617F Allele Burden and Clinical Correlates in Polycythemia Vera: a Systematic Review and Meta-analysis

Overview

Journal Ann Hematol

Specialty Hematology

Date 2024 Apr 23

PMID 38652240

Authors

Chih-Cheng Chen

Justin L Chen

Alex Jia-Hong Lin

Lennex Hsueh-Lin Yu

Hsin-An Hou

Affiliations

Soon will be listed here.

Abstract

Janus kinase 2 (JAK2) V617F mutation is present in most patients with polycythemia vera (PV). One persistently puzzling aspect unresolved is the association between JAK2V617F allele burden (also known as variant allele frequency) and the relevant clinical characteristics. Numerous studies have reported associations between allele burden and both hematologic and clinical features. While there are strong indications linking high allele burden in PV patients with symptoms and clinical characteristics, not all associations are definitive, and disparate and contradictory findings have been reported. Hence, this study aimed to synthesize existing data from the literature to better understand the association between JAK2V617F allele burden and relevant clinical correlates. Out of the 1,851 studies identified, 39 studies provided evidence related to the association between JAK2V617F allele burden and clinical correlates, and 21 studies were included in meta-analyses. Meta-analyses of correlation demonstrated that leucocyte and erythrocyte counts were significantly and positively correlated with JAK2V617F allele burden, whereas platelet count was not. Meta-analyses of standardized mean difference demonstrated that leucocyte and hematocrit were significantly higher in patients with higher JAK2V617F allele burden, whereas platelet count was significantly lower. Meta-analyses of odds ratio demonstrated that patients who had higher JAK2V617F allele burden had a significantly greater odds ratio for developing pruritus, splenomegaly, thrombosis, myelofibrosis, and acute myeloid leukemia. Our study integrates data from approximately 5,462 patients, contributing insights into the association between JAK2V617F allele burden and various hematological parameters, symptomatic manifestations, and complications. However, varied methods of data presentation and statistical analyses prevented the execution of high-quality meta-analyses.

Citing Articles

Cost-utility analysis of ropeginterferon alfa-2b to manage low-risk patients with polycythemia vera as compared to phlebotomy only in the Austrian healthcare system.

Walter E, Torelli F, Barbui T Ann Hematol. 2025; 104(1):219-229.

PMID: 39888353 PMC: 11868240. DOI: 10.1007/s00277-025-06229-w.

References

Barbui T, Carobbio A, Finazzi G, Vannucchi A, Barosi G, Antonioli E . Inflammation and thrombosis in essential thrombocythemia and polycythemia vera: different role of C-reactive protein and pentraxin 3. Haematologica. 2010; 96(2):315-8. PMC: 3031701. DOI: 10.3324/haematol.2010.031070. View

Gangat N, Strand J, Lasho T, Finke C, Knudson R, Pardanani A . Cytogenetic studies at diagnosis in polycythemia vera: clinical and JAK2V617F allele burden correlates. Eur J Haematol. 2007; 80(3):197-200. DOI: 10.1111/j.1600-0609.2007.01003.x. View

Milosevic Feenstra J, Jager R, Schischlik F, Ivanov D, Eisenwort G, Rumi E . PD-L1 overexpression correlates with JAK2-V617F mutational burden and is associated with 9p uniparental disomy in myeloproliferative neoplasms. Am J Hematol. 2022; 97(4):390-400. PMC: 9306481. DOI: 10.1002/ajh.26461. View

Moliterno A, Williams D, Rogers O, Isaacs M, Spivak J . Phenotypic variability within the JAK2 V617F-positive MPD: roles of progenitor cell and neutrophil allele burdens. Exp Hematol. 2008; 36(11):1480-6. PMC: 2600434. DOI: 10.1016/j.exphem.2008.05.006. View

Lee A, Kim S, Nam J, Yun J, Ryoo H, Bae S . Clinical features and outcomes of V617F-positive polycythemia vera and essential thrombocythemia according to the V617F allele burden. Blood Res. 2021; 56(4):259-265. PMC: 8721460. DOI: 10.5045/br.2021.2021089. View

Baxter E, Scott L, Campbell P, East C, Fourouclas N, Swanton S . Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet. 2005; 365(9464):1054-61. DOI: 10.1016/S0140-6736(05)71142-9. View

Zhang Y, Zhou Y, Wang Y, Teng G, Li D, Wang Y . Thrombosis among 1537 patients with JAK2 -mutated myeloproliferative neoplasms: Risk factors and development of a predictive model. Cancer Med. 2020; 9(6):2096-2105. PMC: 7064115. DOI: 10.1002/cam4.2886. View

Sazawal S, Singh K, Chhikara S, Chaubey R, Mahapatra M, Saxena R . Influence of JAK2V617F allele burden on clinical phenotype of polycythemia vera patients: A study from India. South Asian J Cancer. 2019; 8(2):127-129. PMC: 6498707. DOI: 10.4103/sajc.sajc_161_18. View

Barbui T, Thiele J, Passamonti F, Rumi E, Boveri E, Randi M . Initial bone marrow reticulin fibrosis in polycythemia vera exerts an impact on clinical outcome. Blood. 2012; 119(10):2239-41. DOI: 10.1182/blood-2011-11-393819. View

10.

Yang N, Park S, Cho M, Lee M, Hong K, Mun Y . GATA1 Expression in BCR/ABL1-negative Myeloproliferative Neoplasms. Ann Lab Med. 2018; 38(4):296-305. PMC: 5895858. DOI: 10.3343/alm.2018.38.4.296. View

11.

Borowczyk M, Wojtaszewska M, Lewandowski K, Gil L, Lewandowska M, Lehmann-Kopydlowska A . The JAK2 V617F mutational status and allele burden may be related with the risk of venous thromboembolic events in patients with Philadelphia-negative myeloproliferative neoplasms. Thromb Res. 2015; 135(2):272-80. DOI: 10.1016/j.thromres.2014.11.006. View

12.

Zhao S, Zhang X, Xu Y, Feng Y, Sheng W, Cen J . Impact of JAK2V617F Mutation Burden on Disease Phenotype in Chinese Patients with JAK2V617F-positive Polycythemia Vera (PV) and Essential thrombocythemia (ET). Int J Med Sci. 2016; 13(1):85-91. PMC: 4747874. DOI: 10.7150/ijms.10539. View

13.

Luque Paz D, Chauveau A, Boyer F, Buors C, Samaison L, Cottin L . Sequential analysis of 18 genes in polycythemia vera and essential thrombocythemia reveals an association between mutational status and clinical outcome. Genes Chromosomes Cancer. 2016; 56(5):354-362. DOI: 10.1002/gcc.22437. View

14.

Misawa K, Yasuda H, Araki M, Ochiai T, Morishita S, Shirane S . Mutational subtypes of JAK2 and CALR correlate with different clinical features in Japanese patients with myeloproliferative neoplasms. Int J Hematol. 2018; 107(6):673-680. DOI: 10.1007/s12185-018-2421-7. View

15.

Kralovics R, Teo S, Li S, Theocharides A, Buser A, Tichelli A . Acquisition of the V617F mutation of JAK2 is a late genetic event in a subset of patients with myeloproliferative disorders. Blood. 2006; 108(4):1377-80. DOI: 10.1182/blood-2005-11-009605. View

16.

Kovacsovics-Bankowski M, Kelley T, Efimova O, Kim S, Wilson A, Swierczek S . Changes in peripheral blood lymphocytes in polycythemia vera and essential thrombocythemia patients treated with pegylated-interferon alpha and correlation with allelic burden. Exp Hematol Oncol. 2016; 5:28. PMC: 5037882. DOI: 10.1186/s40164-016-0057-y. View

17.

Pieri L, Bogani C, Guglielmelli P, Zingariello M, Rana R, Bartalucci N . The JAK2V617 mutation induces constitutive activation and agonist hypersensitivity in basophils from patients with polycythemia vera. Haematologica. 2009; 94(11):1537-45. PMC: 2770964. DOI: 10.3324/haematol.2009.007047. View

18.

Vadikolia C, Tsatalas C, Anagnostopoulos K, Trypsianis G, Pantelidou D, Bazdiara I . Proteolytic matrix metallopeptidases and inhibitors in BCR-ABL1-negative myeloproliferative neoplasms: correlation with JAK2 mutation status. Acta Haematol. 2011; 126(1):54-62. DOI: 10.1159/000324436. View

19.

Alvarez-Larran A, Angona A, Ancochea A, Garcia-Pallarols F, Fernandez C, Longaron R . Masked polycythaemia vera: presenting features, response to treatment and clinical outcomes. Eur J Haematol. 2015; 96(1):83-9. DOI: 10.1111/ejh.12552. View

20.

Lekovic D, Gotic M, Skoda R, Beleslin-cokic B, Milic N, Mitrovic-Ajtic O . Bone marrow microvessel density and plasma angiogenic factors in myeloproliferative neoplasms: clinicopathological and molecular correlations. Ann Hematol. 2016; 96(3):393-404. DOI: 10.1007/s00277-016-2890-9. View